Condition
Vision Loss
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Completed3
Recruiting1
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07246915Enrolling By Invitation
Long-term Safety & Performance of REVISYON SDS100 in Mild to Moderate Cataract: Extension Study (EB-CE-02)
NCT07073521Not ApplicableRecruiting
Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss
NCT01598818CompletedPrimary
First-Sight Refractive Error Correction in the Developing World
NCT01838655Phase 1Completed
Nitisinone for Type 1B Oculocutaneous Albinism
NCT02862405CompletedPrimary
Perception of Objects and Natural Scenes in People With Vision Loss (ACTIVIS)
Showing all 5 trials